BioCentury
ARTICLE | Clinical News

Thioureidobutyronitrile: Interim Phase I data

August 24, 2015 7:00 AM UTC

Interim data from 1 patient with stage IV thymoma in his eleventh month of treatment in an open-label, dose-escalation, U.S. Phase I trial showed that once-weekly IV Kevetrin for the first 3 weeks of ...